AbbVie makes bold move in Alzheimer’s market with $1.4bn Aliada buyout—Is it a gamble?

AbbVie, the renowned American biopharmaceutical giant, is set to acquire Aliada Therapeutics for a staggering $1.4 billion. The acquisition grants AbbVie control over Aliada’s promising ... Read More